Prima BioMed Ltd. announced the appointment of Stuart Roberts as Global Head of Investor Relations. Mr. Roberts is an experienced investment professional, with expertise in the healthcare and biotechnology sectors, and has been involved in Australian equity research for 16 years. He builds his reputation as one of Australia's leading sell-side biotech analysts and has been working with Baillieu Holst and Bell Potter before joining Prima.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.47 AUD | +3.30% | +3.30% | +36.23% |
05-17 | Capital One Initiates Immutep at Overweight Rating With $10 Price Target | MT |
05-15 | Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.23% | 362M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- IMM Stock
- News Immutep Limited
- Stuart Roberts Appoints Stuart Roberts as Global Head of Investor Relations